UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~CURRENT~~Current ~~REPORT~~Report

Pursuant to Section 13 or 15(d) of the ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~Report~~Act ~~(date~~ of ~~earliest event reported): February 20, 2026~~1934

Date of Report (Date of earliest event reported): March 26, 2026

Insight Molecular Diagnostics Inc.

(Exact name of ~~registrant~~Registrant as specified in its charter)

California	1-37648	27-1041563
(State or other jurisdiction	(Commission	(IRS Employer
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)
of incorporation)	File Number)	Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

(615) 255-8880

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities ~~registered~~Registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common ~~Stock~~stock, no par value IMDX The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 12.~~01.~~02 ~~Entry~~Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition.

On ~~February~~March 2026, 2026, Insight Molecular Diagnostics Inc. (~~the~~“we,” “~~Company~~us,”) ~~entered~~“our,” ~~into a Specimen Collection Agreement (~~the “~~Agreement~~Company”) ~~with~~or ~~Quest Diagnostics Incorporated (~~“~~Quest Diagnostics~~iMDx”). ~~Pursuant~~issued toa ~~the~~press ~~Agreement,~~release ~~Quest~~announcing ~~Diagnostics~~our ~~will~~financial ~~provide~~results ~~certain specimen~~for ~~collection-related~~the ~~services~~three ~~related~~and totwelve ~~specimens~~months ~~upon~~ended ~~which~~December ~~Provider will perform a GraftAssureCore™ test~~31, ~~a blood test~~2025. ~~designed~~A tocopy ~~measure~~of ~~donor-derived~~the ~~cell~~press ~~free~~release ~~DNA~~is ~~(dd-cfDNA)~~furnished ~~using~~as aExhibit ~~novel~~99.1, ~~PCR-based measurement platform~~which, ~~for~~in ~~potential~~its ~~patient~~entirety, ~~registrants. The~~is ~~Agreement~~incorporated ~~provides~~herein ~~for~~by ~~certain fees to be paid to Quest for services rendered~~reference.

InThe ~~addition,~~information ~~each~~in this Item 2.02 of ~~the~~this ~~Company~~Current ~~and~~Report ~~Quest~~on ~~Diagnostics~~Form ~~agree~~8-K, ~~that~~including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for athe ~~specified~~purposes ~~period,~~of Section 18 of the ~~parties~~Securities ~~will~~Exchange ~~use~~Act ~~commercially~~of ~~reasonable~~1934, as amended (the “Exchange Act”), ~~efforts~~or otherwise subject to ~~negotiate~~the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, inas ~~good~~amended, ~~faith~~or the Exchange Act, ~~certain~~whether ~~additional~~made ~~rights~~before toor after the ~~GraftAssure~~date ~~technology~~hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to the full text of the Agreement, a copy of which the Company intends to file as an exhibit to a subsequent periodic report or on an amendment to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).
99.1		Press release dated March 26, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INSIGHT MOLECULAR DIAGNOSTICS INC.
Date: February 26, 2026	By:	/s/ Peter Hong
Date: March 26, 2026	By:	/s/ Peter Hong
		Peter Hong
	Name:	Peter Hong
		Vice President, General Counsel
	Title:	Vice President, General Counsel

Filing Compare · Insight Molecular Diagnostics Inc.